Skip Navigation

Link to  the National Institutes of Health  
The Science of Drug Abuse and Addiction from the National Institute on Drug Abuse Archives of the National Institute on Drug Abuse web site
Go to the Home page
   

National Institute on Drug Abuse -  NIDA NOTES
Bulletin Board
Volume 15, Number 4 (September, 2000)

Conference on Adolescent Substance Abuse For the Practitioner

November 3-5, 2000
Omni Shoreham Hotel Washington, D.C.

American Society of Addiction Medicine in cooperation with:

  • National Institute on Drug Abuse

  • American Academy of Pediatrics

  • American Academy of Child and Adolescent Psychiatry

  • National Institute on Alcohol Abuse and Alcoholism.


NIDA's Buprenorphine Development Team Honored

NIDA staff who contributed to the development of buprenorphine, a medication for treating addiction to heroin and other opiates, were honored at the annual Department of Health and Human Services (HHS) Honor Awards Ceremony in May. The research team was presented with the Secretary's Award for Distinguished Service, which is given each year for service that significantly advances the Department's mission and goals. HHS Secretary Donna Shalala presented the award, which cited the group's "outstanding performance in the development of buprenorphine products as treatment agents for opiate dependence." Dr. Nora Chiang accepted the award on behalf of the research group from NIDA's Division of Treatment Research and Development. Other members of the team were Dr. Peter Bridge, Mr. Lee Cummings, Mr. Joel Egertson, Ms. Liza Gorgon, Dr. Richard Hawks, Dr. Susan Herbert, Dr. James Hill, Dr. Deborah Leiderman, Dr. Moo Park, Dr. Betty Tai, Dr. James Terrill, Mr. Robert Walsh, and Division Director Dr. Frank Vocci.

Buprenorphine is awaiting FDA approval for use. "This is terrific recognition for a group that has done a truly outstanding job bringing to near-release the first new medication for opiate addiction in nearly a decade," said NIDA Director Dr. Alan I. Leshner. "It will be a very important addition to the clinical toolbox that will aid hundreds of thousands of individuals, their families, and their communities."

Members of the Buprenorphine Development Team

Members of the buprenorphine development team in NIDA's Division of Treatment Research and Development with Secretary of Health and Human Services Donna Shalala. From left to right: Mr. Robert Walsh, Dr. James Terrill, Dr. Richard Hawks, Mr. Lee Cummings, Dr. Nora Chiang, Secretary Shalala, Ms. Liza Gorgon, Dr. Moo Park, Mr. Joel Egertson, and Dr. Frank Vocci.

NIDA NOTES - Volume 15, Number 4

[NIDA NOTES Index][Index of this Issue]

Archive Home | Accessibility | Privacy | FOIA (NIH) | Current NIDA Home Page
National Institutes of Health logo_Department of Health and Human Services Logo The National Institute on Drug Abuse (NIDA) is part of the National Institutes of Health (NIH) , a component of the U.S. Department of Health and Human Services. Questions? See our Contact Information. . The U.S. government's official web portal